A PYMNTS Company

Canada: Valeant aims high with 2014 merger spree plans

By  |  January 30, 2014

Valeant Pharmaceuticals has major plans for 2014, including the goal of becoming one of the world’s five-largest pharmaceutical companies. That goal, reports say, includes reaching a market value of more than $150 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Valeant, based in Canada, has upped its market value from less than $3 billion in 2010 to its current value of $44 billion through major acquisitions.

    Now, plans to merge with Actavis could now add yet another boost to its market value this year. Industry experts also note that a deal with Teva Pharmaceuticals could push Valeant in the right direction.

    According to the head of healthcare research at Aegis Capital, Valeant’s $150 billion goal “is actually not unrealistic at all.”

    ”This transaction is going to happen in 2014, and it’s going to be a biggie,” he said.

    Full Content: Businessweek

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.